clinical trial · NCT05883748
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Erythropoietic ProtoporphyriaDISC-1459DISC-1459
brief summary
This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.
started
Aug 31, 2023
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Jun 18, 2026
official title
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol